Research ExplorerPublicationsOptimizing the use of the "state-of-the-art" performance cri...

Optimizing the use of the "state-of-the-art" performance criteria

Standard

Optimizing the use of the "state-of-the-art" performance criteria. / Haeckel, Rainer; Wosniok, Werner; Streichert, Thomas.

In: CLIN CHEM LAB MED, Vol. 53, No. 6, 05.2015, p. 887-91.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Haeckel, R, Wosniok, W & Streichert, T 2015, 'Optimizing the use of the "state-of-the-art" performance criteria', CLIN CHEM LAB MED, vol. 53, no. 6, pp. 887-91. https://doi.org/10.1515/cclm-2014-1201

APA

Haeckel, R., Wosniok, W., & Streichert, T. (2015). Optimizing the use of the "state-of-the-art" performance criteria. CLIN CHEM LAB MED, 53(6), 887-91. https://doi.org/10.1515/cclm-2014-1201

Vancouver

Haeckel R, Wosniok W, Streichert T. Optimizing the use of the "state-of-the-art" performance criteria. CLIN CHEM LAB MED. 2015 May;53(6):887-91. https://doi.org/10.1515/cclm-2014-1201

Bibtex

@article{cf9127db077d41d3af2131473c568e36,
title = "Optimizing the use of the {"}state-of-the-art{"} performance criteria",
abstract = "The organizers of the first EFLM Strategic Conference {"}Defining analytical performance goals{"} identified three models for defining analytical performance goals in laboratory medicine. Whereas the highest level of model 1 (outcome studies) is difficult to implement, the other levels are more or less based on subjective opinions of experts, with models 2 (based on biological variation) and 3 (defined by the state-of-the-art) being more objective. A working group of the German Society of Clinical Chemistry and Laboratory Medicine (DGKL) proposes a combination of models 2 and 3 to overcome some disadvantages inherent to both models. In the new model, the permissible imprecision is not defined as a constant proportion of biological variation but by a non-linear relationship between permissible analytical and biological variation. Furthermore, the permissible imprecision is referred to the target quantity value. The biological variation is derived from the reference interval, if appropriate, after logarithmic transformation of the reference limits.",
keywords = "Clinical Laboratory Techniques, Humans, Observer Variation, Prostate-Specific Antigen, Reference Values, Uncertainty",
author = "Rainer Haeckel and Werner Wosniok and Thomas Streichert",
year = "2015",
month = may,
doi = "10.1515/cclm-2014-1201",
language = "English",
volume = "53",
pages = "887--91",
journal = "CLIN CHEM LAB MED",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "6",

}

RIS

TY - JOUR

T1 - Optimizing the use of the "state-of-the-art" performance criteria

AU - Haeckel, Rainer

AU - Wosniok, Werner

AU - Streichert, Thomas

PY - 2015/5

Y1 - 2015/5

N2 - The organizers of the first EFLM Strategic Conference "Defining analytical performance goals" identified three models for defining analytical performance goals in laboratory medicine. Whereas the highest level of model 1 (outcome studies) is difficult to implement, the other levels are more or less based on subjective opinions of experts, with models 2 (based on biological variation) and 3 (defined by the state-of-the-art) being more objective. A working group of the German Society of Clinical Chemistry and Laboratory Medicine (DGKL) proposes a combination of models 2 and 3 to overcome some disadvantages inherent to both models. In the new model, the permissible imprecision is not defined as a constant proportion of biological variation but by a non-linear relationship between permissible analytical and biological variation. Furthermore, the permissible imprecision is referred to the target quantity value. The biological variation is derived from the reference interval, if appropriate, after logarithmic transformation of the reference limits.

AB - The organizers of the first EFLM Strategic Conference "Defining analytical performance goals" identified three models for defining analytical performance goals in laboratory medicine. Whereas the highest level of model 1 (outcome studies) is difficult to implement, the other levels are more or less based on subjective opinions of experts, with models 2 (based on biological variation) and 3 (defined by the state-of-the-art) being more objective. A working group of the German Society of Clinical Chemistry and Laboratory Medicine (DGKL) proposes a combination of models 2 and 3 to overcome some disadvantages inherent to both models. In the new model, the permissible imprecision is not defined as a constant proportion of biological variation but by a non-linear relationship between permissible analytical and biological variation. Furthermore, the permissible imprecision is referred to the target quantity value. The biological variation is derived from the reference interval, if appropriate, after logarithmic transformation of the reference limits.

KW - Clinical Laboratory Techniques

KW - Humans

KW - Observer Variation

KW - Prostate-Specific Antigen

KW - Reference Values

KW - Uncertainty

U2 - 10.1515/cclm-2014-1201

DO - 10.1515/cclm-2014-1201

M3 - SCORING: Journal article

C2 - 25803083

VL - 53

SP - 887

EP - 891

JO - CLIN CHEM LAB MED

JF - CLIN CHEM LAB MED

SN - 1434-6621

IS - 6

ER -